Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Stryker Acquires Sage Products from Madison Dearborn Partners
Davis Polk is advising JP Morgan as financial adviser to Stryker Corporation in connection with its $2.775 billion…
Biotie acquisition by Acorda
Davis Polk is advising Biotie Therapies Corp. in connection with its combination agreement with Acorda Therapeutics, Inc…
Ardelyx, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers in connection with an $86.2 million SEC-registered follow-on common stock…
Adamas Pharmaceuticals, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers in connection with a $66.1 million SEC-registered common stock offering…
Cempra, Inc. Common Stock Offering
Davis Polk advised the underwriters in connection with the SEC-registered offering of 4,166,167 shares of common stock of…
Davis Polk Advises Affymetrix on Its Sale to Thermo Fisher
Davis Polk is advising Affymetrix, Inc. in connection with its sale to Thermo Fisher Scientific Inc. for a total equity…
Davis Polk Advises Charles River Laboratories on Its Acquisition of WIL Research
Davis Polk is advising Charles River Laboratories International, Inc. on its acquisition of WIL Research for approximately …
Davis Polk Advises China Cinda on a Strategic Investment by Sino Biopharmaceutical
Davis Polk is advising China Cinda Asset Management Co., Ltd. (“China Cinda”) in connection with a proposed strategic…
Mylan N.V. $1 Billion Notes Offering
Davis Polk advised the representatives of the initial purchasers on two Rule 144A/Regulation S offerings by Mylan N.V. of …
Mindray Medical Going-Private Transaction
Davis Polk is advising Lazard Asia (Hong Kong) Limited as financial adviser to the special committee of the board of…